Evidence map›Paper›PMID 37483852›Full record

ArticleCentral European journal of urology2023

Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with urothelial carcinoma of the bladder following radical cystectomy.

Fabio Zattoni, Giacomo Novara, Massimo Iafrate, Filippo Carletti, Giuseppe Reitano, Gianmarco Randazzo, Tommaso Ceccato, Giovanni Betto, Fabrizio Dal Moro

Open access · greenAbstract read
In one paragraph

Article in Central European journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Fabio ZattoniDepartment of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padova, Italy.
Giacomo NovaraDepartment of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padova, Italy.
Massimo IafrateDepartment of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padova, Italy.
Filippo CarlettiDepartment of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padova, Italy.
Giuseppe ReitanoDepartment of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padova, Italy.
Gianmarco RandazzoDepartment of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padova, Italy.
Tommaso CeccatoDepartment of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padova, Italy.
Giovanni BettoDepartment of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padova, Italy.
Fabrizio Dal MoroDepartment of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padova, Italy.
University of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The pre-treatment neutrophil-to-lymphocyte ratio (NLR) has been associated with adverse pathology or survival in a variety of malignancies, including urothelial carcinoma of the bladder (UCB) treated with radical cystectomy (RC). Whether the prognostic value of NLR is retained, or even increased, when measured postoperatively remains to be studied. In this study, we evaluated the association of preoperative and postoperative NLR with oncological outcomes following RC. Material and methods: The NLR was recorded in 132 consecutive patients with UCB treated with open RC: before surgery (NLR1), postoperatively within 2 days (NRL2), between 7 and 15 days after RC before discharge (NLR3), and a few days before recurrence or last available follow-up (NLR4). Results: When assessed by multivariate analysis NLR1 remained independently associated with a significantly increased risk of extravesical disease (pT 3-4) (OR = 1.4, p <0.01) and lymphovascular invasion (LVI) (OR = 1.40, 95% CI 1.09-1.83, p <0.01). NLR4 was independently associated with a significantly increased risk of cancer-specific mortality (CSM) (HR = 1.14, 95%CI 1.03-1.24, p = 0.013). In a postoperative model, NLR3 was found to be an independent predictor of all-cause mortality (ACM) [HR = 1.11, 95% CI 1.02-1.21, p = 0.01]. NLR1 was associated with a significantly increased risk of recurrence in the univariable preoperative model [HR = 1.9, 95%CI 1.00-3.65, p = 0.05], while in the postoperative model NLR4 remained independently associated with a significantly increased risk of recurrence (HR = 1.13, 95%CI 1.04-1.23, p = 0.03). Conclusions: In patients with UCB treated with RC, the NLR is associated with more advanced tumour stage, LVI, lymph node metastasis, and higher CSM. Furthermore, the variation of the NLR after surgery might play a role in predicting higher ACM and recurrence-free survival.

Indexed as

bladderbladder cancerneutrophil-to-lymphocyte ratioNLRprognosticradical cystectomyurothelial carcinoma

Identifiers

PMID37483852
PMCPMC10357830
OpenAlexW4380320588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.